Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00100113
Verified March 2005 by National Institute on Drug Abuse (NIDA). Recruitment status was: Active, not recruiting
The purpose of this study is to assess potential interactions between intravenous (IV) cocaine and 3 doses of GBR 12909.
Condition or disease
Drug: GBR 12909
This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology study that will assess the potential interactions between IV cocaine and 3 escalating oral doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with IV cocaine infusions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must be within 20% ideal body weight and must weigh at least 45 kg.
Must understand the study procedures and provide written informed consent.
Must meet DSM-4 criteria and are non-treatment seeking at time of study.